2026-07-17, 5:51:36 a.m.
Toronto, Ontario — July 17, 2026 — Leads & Copy — Red Light Holland Corp., a company operating in the natural psychedelic drug discovery sector, has announced its intention to change its corporate name to Rhelion Life Sciences Corp. This rebranding, pending approval from the Canadian Securities Exchange (CSE), signifies a strategic shift towards becoming a focused, science-driven organization specializing in psychedelic drug discovery, development, and innovation.
The name change follows the company’s completed acquisition of Filament Health Corp. and aims to reflect its evolution into a clinical and research-led enterprise. Under the new name, Rhelion Life Sciences intends to leverage Filament’s patented, naturally derived psilocybin drug candidate, PEX010, and its existing network of clinical and compassionate use partners. The company also plans to advance an ambitious new research and development program.
The rebrand, which includes a new website (www.Rhelion.com), comes amid growing momentum and investor interest in the psychedelic sector. This trend was highlighted on July 16, 2026, with Eli Lilly and Company’s agreement to acquire AtaiBeckley for up to US$3.8 billion, a significant transaction indicating rising interest from major pharmaceutical companies in clinically de-risked psychedelic assets.
“This name change represents so much more than a new name. It represents everything we have been building toward when it comes to increasing responsible and standardized psychedelic access – from underground to mainstream,” said Todd Shapiro, Chief Executive Officer and Director of the Company. “Rhelion reflects the company we have become: a science first, research driven organization with a world class drug development platform, a growing program, and a bold vision for the future of natural psychedelic medicine. The timing is perfect. The sector is gaining real momentum, major pharmaceutical companies are moving decisively into psychedelics, and we intend to build genuine, de-risked value for our shareholders. Rhelion Life Sciences: Rediscover Health represents the next evolution of science-backed innovation focused on long-term mental wellness and conscious human advancement.”
The company has enhanced its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities to support the development of naturally derived psilocybin and Filament’s PEX010. Recently, Filament Health introduced a new 0.5 mg dose for PEX010, adding to its existing 1, 5, and 25 mg strengths. This provides researchers with a standardized dosing range from sub-hallucinogenic microdosing to full therapeutic doses. PEX010 is produced using Filament’s proprietary extraction, purification, and stabilization methods, ensuring a potent, standardized, and patented botanical drug product with consistent composition across all doses and studies. This consistency is supported by an international patent portfolio and a demonstrated 36-month shelf life, offering reproducibility and preventing batch-to-batch variation.
This development, coupled with the company’s future-focused direction, addresses the ongoing demand for pharmaceutical-grade, naturally derived psilocybin and the expanding role of PEX010 in academic and clinical research. It also reinforces the operational and quality systems essential for reliable global supply. PEX010 has been supplied to over 80 academic and philanthropic research studies globally, including trials at prominent institutions such as Imperial College, Johns Hopkins University, the University of California, San Francisco, and McGill University.
Rhelion Life Sciences believes the new brand will better communicate its mission to patients, researchers, partners, regulators, and investors, providing a unified identity for advancing its clinical, research, and commercialization objectives on a global scale. Further details regarding the name change and its final approval, including any effective date and changes to trading symbols, will be announced in a subsequent press release.
About Rhelion Life Sciences Corp (formerly Red Light Holland):
Rhelion Life Sciences Corp. (formerly Red Light Holland Corp.) is a science and research-led company advancing the natural psychedelic drug discovery and development sector. Through its subsidiary Filament Health Corp., the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions worldwide. The company also operates in the Netherlands’ legal adult-use market and supports voluntary data collection and research to advance the scientific understanding of natural psychedelics.
Source: Rhelion Life Sciences Corp
